ECSP003508A - Formas polimorfas de un citrato de azobiciclo [2.2.2] octan-3-amina y sus composiciones farmaceuticas - Google Patents
Formas polimorfas de un citrato de azobiciclo [2.2.2] octan-3-amina y sus composiciones farmaceuticasInfo
- Publication number
- ECSP003508A ECSP003508A EC2000003508A ECSP003508A ECSP003508A EC SP003508 A ECSP003508 A EC SP003508A EC 2000003508 A EC2000003508 A EC 2000003508A EC SP003508 A ECSP003508 A EC SP003508A EC SP003508 A ECSP003508 A EC SP003508A
- Authority
- EC
- Ecuador
- Prior art keywords
- citrate
- octan
- azobiciclo
- amina
- pharmaceutical compositions
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 title abstract 2
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 abstract 2
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- JASMWYNKLTULAN-UHFFFAOYSA-N octan-3-amine Chemical compound CCCCCC(N)CC JASMWYNKLTULAN-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Una forma polimorfa cristalina individual del citrato de (2S,3S) -(metoxi-5-t-buti!fenilmetil-2-difenilmetil-I-azobiciclo[2,2,2) octan-3-amina (citrato monohidrato) y su composición farmacéutica. La composición farmacéutica de la forma polimorfa si el citrato monohidrato tiene la estabilidad necesaria para una formulación para tratar la emesis. La administración de esta composición farmacéutica es una forma de dosificación oral de liberación inmediata, preferiblemente en forma de comprimido o cápsula, o intravenosa.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13699299P | 1999-06-01 | 1999-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP003508A true ECSP003508A (es) | 2002-02-25 |
Family
ID=22475338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2000003508A ECSP003508A (es) | 1999-06-01 | 2000-06-01 | Formas polimorfas de un citrato de azobiciclo [2.2.2] octan-3-amina y sus composiciones farmaceuticas |
Country Status (48)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2554823A1 (en) | 2004-01-30 | 2005-09-09 | Pfizer Products Inc. | Nk-1 receptor antagonists to improve anesthesia recovery |
| EP1713506A1 (en) * | 2004-01-30 | 2006-10-25 | Pfizer Products Incorporated | Pharmaceutical compositions of neurokinin receptor antagonists and cyclodextrin and methods for improved injection site toleration |
| LT1713504T (lt) * | 2004-01-30 | 2017-09-11 | Zoetis Services Llc | Antimikrobinis konservantas, skirtas multi-dozinėms kompozicijoms, panaudojant beta-ciklodekstrinus, skirtas skystoms vaisto formoms |
| SI1713801T1 (sl) * | 2004-02-02 | 2008-04-30 | Pfizer Prod Inc | Postopek priprave 1-(2S,3S)-2-benzhidril-N-(5-terc-butil-2-metoksibenzil)kinuklidin-3- amina |
| KR102391332B1 (ko) * | 2013-03-15 | 2022-04-26 | 펄 테라퓨틱스 인코포레이티드 | 미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템 |
| CN110577522B (zh) * | 2018-06-07 | 2022-12-27 | 东莞市东阳光动物保健药品有限公司 | 马罗匹坦柠檬酸盐新晶型及其制备方法 |
| CN112979639B (zh) * | 2019-12-16 | 2025-08-08 | 凯默斯医药科技(上海)有限公司 | 一种马罗皮坦新晶型及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU657552B2 (en) * | 1991-05-31 | 1995-03-16 | Pfizer Inc. | Quinuclidine as substance P antagonists |
| US5393762A (en) * | 1993-06-04 | 1995-02-28 | Pfizer Inc. | Pharmaceutical agents for treatment of emesis |
| US5576317A (en) * | 1994-12-09 | 1996-11-19 | Pfizer Inc. | NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis |
-
2000
- 2000-05-08 US US09/566,307 patent/US6255320B1/en not_active Expired - Lifetime
- 2000-05-17 HN HN2000000077A patent/HN2000000077A/es unknown
- 2000-05-18 DK DK00925528T patent/DK1181290T3/da active
- 2000-05-18 KR KR10-2001-7015494A patent/KR100476606B1/ko not_active Expired - Fee Related
- 2000-05-18 EP EP00925528A patent/EP1181290B1/en not_active Expired - Lifetime
- 2000-05-18 DE DE60003679T patent/DE60003679T2/de not_active Expired - Lifetime
- 2000-05-18 AP APAP/P/2001/002349A patent/AP2001002349A0/en unknown
- 2000-05-18 NZ NZ515349A patent/NZ515349A/xx unknown
- 2000-05-18 HR HR20010904A patent/HRP20010904A2/hr not_active Application Discontinuation
- 2000-05-18 SK SK1733-2001A patent/SK285820B6/sk not_active IP Right Cessation
- 2000-05-18 PT PT00925528T patent/PT1181290E/pt unknown
- 2000-05-18 WO PCT/IB2000/000665 patent/WO2000073304A1/en not_active Ceased
- 2000-05-18 HU HU0201301A patent/HUP0201301A3/hu unknown
- 2000-05-18 AT AT00925528T patent/ATE244239T1/de not_active IP Right Cessation
- 2000-05-18 CZ CZ20014269A patent/CZ295819B6/cs not_active IP Right Cessation
- 2000-05-18 IL IL14640600A patent/IL146406A0/xx not_active IP Right Cessation
- 2000-05-18 MX MXPA01012325A patent/MXPA01012325A/es unknown
- 2000-05-18 OA OA1200100318A patent/OA11956A/en unknown
- 2000-05-18 PL PL00352716A patent/PL196046B1/pl not_active IP Right Cessation
- 2000-05-18 TR TR2001/03473T patent/TR200103473T2/xx unknown
- 2000-05-18 JP JP2001500629A patent/JP3830816B2/ja not_active Expired - Lifetime
- 2000-05-18 SI SI200030161T patent/SI1181290T1/xx unknown
- 2000-05-18 CN CNB008082782A patent/CN1146565C/zh not_active Expired - Lifetime
- 2000-05-18 CA CA002372238A patent/CA2372238C/en not_active Expired - Lifetime
- 2000-05-18 ES ES00925528T patent/ES2199825T3/es not_active Expired - Lifetime
- 2000-05-18 EA EA200101108A patent/EA003731B1/ru active Protection Beyond IP Right Term
- 2000-05-18 UA UA2001118214A patent/UA66925C2/uk unknown
- 2000-05-18 BR BR0011094-9A patent/BR0011094A/pt not_active Application Discontinuation
- 2000-05-18 AU AU44248/00A patent/AU767334B2/en not_active Expired
- 2000-05-18 EE EEP200100656A patent/EE200100656A/xx unknown
- 2000-05-18 YU YU81101A patent/YU81101A/sh unknown
- 2000-05-23 PA PA20008496101A patent/PA8496101A1/es unknown
- 2000-05-26 TW TW089110206A patent/TWI285204B/zh not_active IP Right Cessation
- 2000-05-26 CO CO00039195A patent/CO5170463A1/es not_active Application Discontinuation
- 2000-05-29 UY UY26176A patent/UY26176A1/es not_active Application Discontinuation
- 2000-05-30 AR ARP000102663A patent/AR033331A1/es active IP Right Grant
- 2000-05-30 MY MYPI20002409A patent/MY133508A/en unknown
- 2000-05-30 PE PE2000000520A patent/PE20010209A1/es not_active Application Discontinuation
- 2000-05-31 MA MA25997A patent/MA26742A1/fr unknown
- 2000-05-31 SV SV2000000093A patent/SV2001000093A/es unknown
- 2000-05-31 TN TNTNSN00120A patent/TNSN00120A1/fr unknown
- 2000-05-31 GT GT200000087A patent/GT200000087A/es unknown
- 2000-05-31 DZ DZ000101A patent/DZ3050A1/xx active
- 2000-06-01 EC EC2000003508A patent/ECSP003508A/es unknown
-
2001
- 2001-11-28 ZA ZA200109775A patent/ZA200109775B/en unknown
- 2001-11-30 NO NO20015848A patent/NO20015848L/no not_active Application Discontinuation
- 2001-12-10 BG BG106204A patent/BG65240B1/bg unknown
-
2007
- 2007-03-27 CY CY2007011C patent/CY2007011I2/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2009001682A1 (es) | Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00). | |
| DK0954314T3 (da) | Doseringsformer til bedring af mandlig erektionsdefekt | |
| BR0206695A (pt) | Formas de dosagem de epotilonas para administração oral | |
| EA200901393A1 (ru) | Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат | |
| BR0114100A (pt) | Formulações de liberação controlada para administração oral | |
| AR001765A1 (es) | Una formulación de liberación prolongada un procedimiento para su preparación una forma cristalina de cisaprida-(l)-tartrato y un medicamento util para el tratamiento de trastornos gastrointestinales | |
| ECSP003508A (es) | Formas polimorfas de un citrato de azobiciclo [2.2.2] octan-3-amina y sus composiciones farmaceuticas | |
| ECSP003538A (es) | Polimorfos de un diclorhidrato cristalino de azobiciclo [2.2.2.] oct-3-ilamina y sus composiciones farmaceuticas | |
| UY28457A1 (es) | Nueva composición | |
| MY141008A (en) | Oral formulations of deoxypeganine and their uses | |
| UY26177A1 (es) | Polimorfos de un citrato de azobiciclo (2.2.2) oct-3- ilamina cristalino y sus composiciones farmacéuticas. | |
| HUP0400495A2 (hu) | Apomorfin szájnyálkahártyán keresztül történő adagolására szolgáló orális készítmény | |
| DE50010973D1 (de) | Pharmazeutische zusammensetzung, enthaltend desoxypeganin zur behandlung des alkoholismus | |
| IT1293835B1 (it) | Composizioni farmaceutiche orali in forma solida a cessione modulata contenenti nicorandil e procedimento per la loro preparazione | |
| ECSP003510A (es) | Polimorfos de un citrato de azobiciclo (2,2,2) oct - 3 - ilamina cristalino y sus composiciones farmaceuticas | |
| GT200000104A (es) | Polimorfos de un diclorhidrato cristalino de azobiciclo 2.2.2 oct - 3 - ilamina y sus composicionesfarmaceuticas. | |
| ATE429905T1 (de) | Pharmazeutische zusammensetzung, enthaltend oxcarbazepin mit kontrollierter wirkstofffreisetzung | |
| MY145885A (en) | Controlled release formulations for oral administration | |
| UY27122A1 (es) | Una composición farmacéutica que comprende de 2 a 4 mg de 5-(a-(2-(n-metil-n-(2-piridil)amino)etoxi)bencil)tiazolidin-2,4-diona | |
| UY27771A1 (es) | Procedimiento para preparar composiciones farmacéuticas de 2 a 8 mg de 5- (4-(2-(n-metil.n(2-piridilo) amino) etoxi) bencilo) tiazolidino-2,4-diona. | |
| PE20090292A1 (es) | Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante | |
| ECSP982396A (es) | Composiciones que contienen tetrahidrolipstatina |